G. Turashvili and E. Brogi, Tumor Heterogeneity in Breast Cancer, Front Med (Lausanne), vol.4, p.227, 2017.

W. D. Foulkes, I. E. Smith, and J. S. Reis-filho, Triple-negative breast cancer, N Engl J Med, vol.363, 1938.
URL : https://hal.archives-ouvertes.fr/hal-02463255

V. Guarneri, Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors, J Clin Oncol, vol.24, pp.1037-1044, 2006.

C. Liedtke, Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer, J Clin Oncol, vol.26, pp.1275-1281, 2008.

M. F. Rimawi, Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes, Cancer, vol.116, pp.1234-1242, 2010.

C. Omarini, Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going, Cancer Manag Res, vol.10, pp.91-103, 2018.

Z. Sporikova, V. Koudelakova, R. Trojanec, and M. Hajduch, Genetic Markers in Triple-Negative Breast Cancer, Clin Breast Cancer, vol.18, pp.841-850, 2018.

D. Kazandjian, FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer, Clin Cancer Res, vol.22, pp.1307-1312, 2016.

S. Al-mahmood, J. Sapiezynski, O. B. Garbuzenko, and T. Minko, Metastatic and triple-negative breast cancer: challenges and treatment options, Drug Deliv Transl Res, vol.8, pp.1483-1507, 2018.

J. Baselga, Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer, J Clin Oncol, vol.23, pp.5323-5333, 2005.

F. Vara and J. A. , PI3K/Akt signalling pathway and cancer, Cancer Treat Rev, vol.30, p.7, 2004.

P. F. Mcauliffe, F. Meric-bernstam, G. B. Mills, and A. M. Gonzalez-angulo, Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis, Clin Breast Cancer, vol.10, issue.3, pp.59-65, 2010.

P. Cossu-rocca, Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer, Scientific RepoRtS |, vol.10, p.6367, 2015.

K. Stemke-hale, An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer, Cancer Res, vol.68, pp.6084-6091, 2008.

M. Laplante and D. M. Sabatini, mTOR signaling in growth control and disease, Cell, vol.149, pp.274-293, 2012.

J. Baselga, Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer, N Engl J Med, vol.366, pp.520-529, 2012.

R. L. Costa, H. S. Han, and W. J. Gradishar, Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review, Breast Cancer Res Treat, vol.169, pp.397-406, 2018.

R. J. Motzer, Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial, Lancet, vol.372, pp.61039-61048, 2008.

J. C. Yao, Everolimus for advanced pancreatic neuroendocrine tumors, N Engl J Med, vol.364, pp.514-523, 2011.

Y. Huang, Y. Chen, Q. Mei, S. Yu, and S. Xia, Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds, Oncol Rep, vol.29, pp.2486-2492, 2013.

L. Monica and S. , Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines, Biochem Pharmacol, vol.78, pp.460-468, 2009.
URL : https://hal.archives-ouvertes.fr/hal-00497268

B. Li, Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells, Oncol Rep, vol.28, pp.15-20, 2012.

T. Liu, Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells, Mol Cancer Ther, vol.10, pp.1460-1469, 2011.

B. D. Lehmann, Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies, J Clin Invest, vol.121, pp.2750-2767, 2011.

R. M. Neve, A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes, Cancer Cell, vol.10, pp.515-527, 2006.

A. El-guerrab, M. Bamdad, Y. J. Bignon, F. Penault-llorca, and C. Aubel, Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells, Mol Carcinog, vol.56, pp.1383-1394, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01671367

A. El-guerrab, Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triplenegative breast cancer, Oncotarget, vol.7, pp.73618-73637, 2016.

T. C. Chou, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies, Pharmacol Rev, vol.58, pp.621-681, 2006.

K. J. Livak and T. D. Schmittgen, Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method, Methods, vol.25, pp.402-408, 2001.

F. Kwiatkowski, M. Girard, K. Hacene, and J. Berlie, Sem: a suitable statistical software adaptated for research in oncology, Bull Cancer, vol.87, pp.715-721, 2000.

A. Gombos, P. Barthelemy, and A. Awada, Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer, Expert Opin Drug Metab Toxicol, vol.11, pp.823-834, 2015.

D. Mckillop, Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, Mol Cancer Ther, vol.4, pp.641-649, 2005.

M. Scheffler, P. Di-gion, O. Doroshyenko, J. Wolf, and U. Fuhr, Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines, Clin Pharmacokinet, vol.50, pp.371-403, 2011.

R. B. Verheijen, Pharmacokinetic Optimization of Everolimus Dosing in Oncology: A Randomized Crossover Trial, Clin Pharmacokinet, vol.57, pp.637-644, 2018.

V. G. Abramson, B. D. Lehmann, T. J. Ballinger, and J. A. Pietenpol, Subtyping of triple-negative breast cancer: implications for therapy, Cancer, vol.121, pp.8-16, 2015.

S. Dong, Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors, Cancer Chemother Pharmacol, vol.70, pp.707-716, 2012.

B. R. Balsara, Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions, Carcinogenesis, vol.25, pp.2053-2059, 2004.

Y. Kokubo, Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA), Br J Cancer, vol.92, pp.1711-1719, 2005.

J. A. Engelman, Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer, J Clin Invest, vol.116, pp.2695-2706, 2006.

Q. Wang, Combination of mTOR and EGFR kinase inhibitors blocks mTORC1 and mTORC2 kinase activity and suppresses the progression of colorectal carcinoma, PLoS One, vol.8, 2013.

R. Bianco, Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors, Oncogene, vol.22, pp.2812-2822, 2003.

M. L. Sos, PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR, Cancer Res, vol.69, pp.3256-3261, 2009.

A. Carracedo, Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer, J Clin Invest, vol.118, pp.3065-3074, 2008.

S. Y. Sun, Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition, Cancer Res, vol.65, pp.7052-7058, 2005.

, Comprehensive molecular portraits of human breast tumours, Nature, vol.490, pp.61-70, 2012.

M. Kriegsmann, Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences, Oncotarget, vol.5, pp.9952-9965, 2014.

S. P. Shah, The clonal and mutational evolution spectrum of primary triple-negative breast cancers, Nature, vol.486, pp.395-399, 2012.